Brainstorm Cell Therapeutics Inc. (BCLI) analyst actions
Rating and price-target actions on BCLI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BCLI overview →
1 measured BCLI analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation | Press release | +4.67% | +3.57% |
Keep exploring
More BCLI: earnings → · SEC filings → · BCLI overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | 664 | -0.07% | 48% |
| UroGen Pharma Ltd. - Ordinary Shares (URGN) | 664 | +0.13% | 53% |
| OPHTHOTECH CORP COMMON (OPHT) | 660 | -0.20% | 43% |
| Gritstone bio, Inc. (GRTS) | 659 | -0.01% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.